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Table 1. Convulsion severity, percentage of death per group, death latency and first
convulsion latency in the animals treated with pentylenetetrazole and in the groups
treated with pentylenetetrazole and venlafaxine at the doses of 25, 50, 75, 100 and
150 mg/kg.
Groups (N = 8) Convulsion Death (%) Death First convulsion
severity latency (s) latency (s)
Saline 3 (3-3) 0 NA1 55 ± 2
Venla (25 mg/kg) 3 (3-3) 12 1665 ± 135 66 ± 4
Venla (50 mg/kg) 3 (3-3.5) 12 1636 ± 164 65 ± 5
Venla (75 mg/kg) 4 (4-4.5)+ 50* 1137 ± 256 52 ± 5
Venla (100 mg/kg) 4 (4-4.5)+ 38* 1281 ± 254 52 ± 4
Venla (150 mg/kg) 4 (4-5)+ 88** 999 ± 146+ NA2
Latencies to death and to first convulsion are expressed as mean ± SEM and convul-
sion severity as median with range in parentheses. NA1 = not available; no animal in
this group died during the cut-off time to 1800 s. NA2 = not available; all animals in this
group developed seizures prior to pentylenetetrazole administration. Venla =
venlafaxine.
*P<0.05 and **P<0.01 (chi-square test).
+P<0.01 (Kruskal-Wallis test followed by the Mann-Whitney test).
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